XENON PHARMACEUTICALS INC (XENE) — insider trading
Health Care · NASDAQ
XENON PHARMACEUTICALS INC (XENE) has 47 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 7 open-market sales among the most recent 47 (latest 2026-09-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | MORTIMER IAN | Director, Officer (PRESIDENT & CEO) | Open-market purchase | 30,000 | $37.38 | $1.12M | Form 4 |
| 2026-09-30 | Kelly Thomas Patrick | Officer (Chief Financial Officer) | Open-market purchase | 15,000 | $37.32 | $559.7K | Form 4 |
| 2026-09-01 | Svoronos Dawn | Director | Option exercise / conversion (derivative) | 5,144 | — | $0 | Form 4 |
| 2026-09-01 | Svoronos Dawn | Director | Option exercise / conversion | 5,144 | $8.15 | $41.9K | Form 4 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Officer (Chief Medical Officer) | Open-market sale | 700 | $60.98 | $42.7K | Form 4 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Officer (Chief Medical Officer) | Open-market sale | 6,368 | $60.17 | $383.1K | Form 4 |
| 2026-08-11 | GANNON STEVEN | Director | Open-market sale | 10,000 | $64.06 | $640.5K | Form 4 |
| 2026-06-05 | Cannon Gillian | Director | Open-market sale | 1,190 | $53.14 | $63.2K | Form 4 |
| 2026-06-05 | PATOU GARY | Director | Open-market sale | 1,322 | $53.14 | $70.3K | Form 4 |
| 2026-06-03 | Svoronos Dawn | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | Svoronos Dawn | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-03 | Cannon Gillian | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | Cannon Gillian | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-03 | GANNON STEVEN | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | GANNON STEVEN | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-03 | GAROFALO ELIZABETH A. | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | GAROFALO ELIZABETH A. | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-03 | Gover Justin D. | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | Gover Justin D. | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-03 | Machado Patrick | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | Machado Patrick | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-03 | PATOU GARY | Director | Grant / award / vesting (derivative) | 1,593 | — | $0 | Form 4 |
| 2026-06-03 | PATOU GARY | Director | Grant / award / vesting (derivative) | 10,507 | — | $0 | Form 4 |
| 2026-06-01 | Svoronos Dawn | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | Svoronos Dawn | Director | Shares withheld for taxes / exercise cost | 1,416 | $53.41 | $75.6K | Form 4 |
| 2026-06-01 | Svoronos Dawn | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-06-01 | Cannon Gillian | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | Cannon Gillian | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-06-01 | GANNON STEVEN | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | GANNON STEVEN | Director | Shares withheld for taxes / exercise cost | 1,416 | $53.41 | $75.6K | Form 4 |
| 2026-06-01 | GANNON STEVEN | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-06-01 | GAROFALO ELIZABETH A. | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | GAROFALO ELIZABETH A. | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-06-01 | Gover Justin D. | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | Gover Justin D. | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-06-01 | Machado Patrick | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | Machado Patrick | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-06-01 | PATOU GARY | Director | Option exercise / conversion (derivative) | 2,645 | — | $0 | Form 4 |
| 2026-06-01 | PATOU GARY | Director | Option exercise / conversion | 2,645 | — | — | Form 4 |
| 2026-05-12 | GANNON STEVEN | Director | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-05-12 | GANNON STEVEN | Director | Option exercise / conversion | 3,500 | $7.38 | $25.8K | Form 4 |
| 2026-03-13 | DiFabio Andrea | Officer (Chief Legal Officer) | Open-market sale | 1,342 | $55.23 | $74.1K | Form 4 |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN | Officer (Chief Medical Officer) | Open-market sale | 1,410 | $55.23 | $77.9K | Form 4 |
| 2026-03-12 | DiFabio Andrea | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-03-12 | DiFabio Andrea | Officer (Chief Legal Officer) | Option exercise / conversion | 3,750 | — | — | Form 4 |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | Officer (Chief Medical Officer) | Option exercise / conversion | 3,750 | — | — | Form 4 |
Ask the chat about XENE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: XENON PHARMACEUTICALS INC (XENE).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.